当前位置：
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Correction to Lancet Oncol 2024; 25: 1325–36
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-10-28 , DOI: 10.1016/s1470-2045(24)00587-4
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-10-28 , DOI: 10.1016/s1470-2045(24)00587-4
Iliopoulos O, Iversen AB, Narayan V, et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol 2024; 25: 1325–36—In this Article, the second sentence in the fifth paragraph of the Results section, should read “After initiating belzutifan treatment, one patient (2%) underwent two CNS-related surgeries (cyst drainage and haemangioblastoma removal for the same lesion), and one patient (2%) received local radiotherapy approximately 5 weeks after starting belzutifan treatment.” These corrections have been made to the online version as of Oct 28, 2024.
更新日期：2024-10-28
京公网安备 11010802027423号